Timeframe for 2015, page-54

  1. 31,485 Posts.
    lightbulb Created with Sketch. 2088
    madamswer

    You did shout me down on my quite accurate forecasting that the FDA would ease up on clinical trials for stem cell therapies.

    Why deny it? You demand that I do the work of trawling through all your long winded posts to find the one where you did that?

    Forget your denials, why can't you just say that I was right about it? (Because I was!)

    The plan to get products to market early was not changed now, it has been changed a while back.

    When that happened you claimed this was a bad thing because it showed Teva was desperate.

    You also have claimed that MSB is short of funds.

    Now you claim that the change in policy about the patient numbers is related to some kind of fragility you keep imagining underscores the Teva partnership. It's damning with faint praise to say "Kudos to management", a strategy to manage an imaginary partnership problem that you keep saying exists, but there is no evidence for. Tricky tricky!

    So many claims and you would have me trawl back through all your months of prolific posts to find them?

    Spare us.

    People are more likely to read the facts in front of them, now in the anns than bother with this series of denials of yours, both contextual and literal.

    The facts are in the anns.
    Last edited by dolcevita: 13/02/15
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.68
Change
-0.165(8.97%)
Mkt cap ! $2.140B
Open High Low Value Volume
$1.81 $1.83 $1.67 $14.80M 8.635M

Buyers (Bids)

No. Vol. Price($)
1 300 $1.67
 

Sellers (Offers)

Price($) Vol. No.
$1.68 2000 1
View Market Depth
Last trade - 16.20pm 02/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.